Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID-19 vaccines less effective in cancer patients receiving chemotherapy

12/02/2021 | 11:21am EST

COVID-19 vaccines offer less protection in people with cancer undergoing chemotherapy, but are still better than no protection at all, a study published Thursday by JAMA Oncology found.

Cancer patients who received chemotherapy within three months of their first dose of either the Moderna or Pfizer-BioNTech vaccines had a 57% lower risk for symptomatic illness following COVID-19 infection after being fully vaccinated than those who were not vaccinated, the data showed.

However, women with breast cancer treated with endocrine, or hormone, therapy within three months of getting vaccinated had 76% protection against the virus after becoming fully vaccinated.

Meanwhile, cancer patients who had not undergone treatment of any kind for at least six months before receiving the COVID-19 vaccine had 85% protection against the virus once they became fully vaccinated, according to the researchers.

People are considered fully vaccinated 14 days after receiving the second dose of either the Moderna or Pfizer-BioNTech vaccines, both of which require two shots.

Cancer patients who received the one-dose Johnson & Johnson vaccine were excluded from the analysis, the researchers said.

"COVID-19 vaccines are effective in patients with cancer, but effectiveness appears to be reduced in certain groups, especially those actively receiving chemotherapy and those who are immunocompromised for another reason," study co-author Nathanael R. Fillmore told UPI in an email.

"However, for some other groups, such as those receiving only endocrine therapy, effectiveness appears to be similar to that observed in the general population," said Fillmore, associate director for machine learning and advanced analytics with the VA Boston Healthcare System.

The Moderna and Pfizer-BioNTech vaccines lower the risk for serious illness following COVID-19 infection by more than 90% in those who are fully vaccinated, studies by the Centers for Disease Control and Prevention found.

That figure, howver, is for currently circulating variants of the virus -- such as the Delta strain, and not the new Omicron strain -- and for people who are not immunocompromised, meaning they do not have weakened immune systems.

Previous studies have found that people with cancer and those undergoing certain treatments for the disease have weakened immune systems and thus poorer responses to the COVID-19 vaccines, indicating the need for booster doses.

Still, given the increased risk for serious illness and death from COVID-19 for people with cancer, vaccination is vital, researchers say.

For this study, Fillmore and his colleagues analyzed data on more than 29,000 cancer patients who were fully vaccinated against COVID-19 and compared infection rates within this population to those of a similar number of unvaccinated cancer patients.

Within an average of seven weeks after becoming fully vaccinated, 161 study participants in the vaccinated group tested positive for COVID-19, while 275 in the unvaccinated group tested positive.

There were 17 COVID-19-related deaths in the vaccinated group and 27 in the unvaccinated group, the researchers said.

Vaccine efficacy for all cancer patients in the study, whether or not they had recently undergone treatment, was 58%.

"Our findings suggest that vaccines may not be as effective at preventing infections in some groups of patients with cancer, meaning that these patients may still be at risk of becoming infected even though they are vaccinated," Fillmore said.

"Thus, even after vaccination, these patients may need to continue to exercise caution and limit their exposure to potential infection," he said.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

All news about MODERNA, INC.
01/21Moderna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
MT
01/21Boosters provide 'added protection' against Omicron -CDC
RE
01/21Small children getting less sick from Omicron; Genetic mutation protects against severe..
RE
01/21Booster shots needed against omicron, CDC studies show
AQ
01/21U.S. studies highlight the need for COVID boosters to fight Omicron
RE
01/21CDC : Vaccines less effective against Omicron, but still reduce risk for serious illness
AQ
01/21UBS Initiates Coverage on Moderna With Neutral Rating, $221 Price Target
MT
01/21BofA Securities Upgrades Moderna to Neutral From Underperform, Adjusts Price Target to ..
MT
01/20Moderna says aims to name 'country of choice' for COVID vaccine production in Africa so..
RE
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 563 M - -
Net income 2021 11 122 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,05x
Yield 2021 -
Capitalization 64 900 M 64 900 M -
EV / Sales 2021 3,14x
EV / Sales 2022 2,05x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 160,07 $
Average target price 276,00 $
Spread / Average Target 72,4%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508
CELLTRION, INC.-17.42%19 126